In a large meta-analysis of 31 studies with 6123 HCM patients, MYBPC3 variant carriers (20% of all HCM patients) had less cardiac conduction disease, less ventricular arrythmia and less HTx (present in 15%, 20% and 0.6% of all MYBPC3 variant carriers respectively) compared to MYH7 variant carriers (Sedaghat-Hamedani et al., 2018). Here, MYBPC3 is linked to heart conduction disease.